RecruitingNCT06547710
Primary Tumor Resection for M1a Stage Lung Cancer
Primary Tumor Resection for M1a Stage Lung Cancer With Occult Pleural Dissemination Discovered During Surgery: a Prospective, Single-arm, Multi-center, Phase Ⅱ Trial
Sponsor
Fudan University
Enrollment
66 participants
Start Date
Apr 1, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1023. This study aims to explore the safety and efficacy of primary lesion resection in the treatment of M1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the OS and quality of life of the corresponding patients.
Eligibility
Min Age: 18 YearsMax Age: 75 Years
Inclusion Criteria8
- Volunteer to participate in clinical research, willing to follow and able to complete all trial procedures;
- Aged 18-80 years (including critical values) when signing the informed consent form;
- ECOG score 0 or 1;
- No previous lung cancer surgery;
- Intraoperative or postoperative pathological confirmation of M1a stage lung cancer;
- Occult pleural metastasis found during surgery;
- Preoperative lymph node staging is cN0;
- First-time treatment and no radiotherapy or chemotherapy.
Exclusion Criteria4
- The lesion cannot be completely removed surgically;
- Cytological or histological pathology confirms other lung malignancies other than lung cancer;
- Patients who have undergone lung cancer surgery before;
- Patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06547710
Related Trials
Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer
NCT054520051 location
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain
NCT054190767 locations
Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer
NCT070261101 location
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
NCT0507804740 locations
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer
NCT065380121 location